1353998-04-5

Basic information

• Product Name: (R)-3-Mercapto-piperidine-1-carboxylic acid benzyl ester
• Synonyms: (R)-3-Mercapto-piperidine-1-carboxylic acid benzyl ester
• CAS NO: 1353998-04-5
• Molecular Formula: C13H17NO2S
• Molecular Weight: 251.34458
• Mol File: 1353998-04-5.mol
• Article Data: 2

Chemical Properties

• Appearance: /
• CAS DataBase Reference: (R)-3-Mercapto-piperidine-1-carboxylic acid benzyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: (R)-3-Mercapto-piperidine-1-carboxylic acid benzyl ester(1353998-04-5)
• EPA Substance Registry System: (R)-3-Mercapto-piperidine-1-carboxylic acid benzyl ester(1353998-04-5)

Safety Data

• Hazardous Substances Data: 1353998-04-5(Hazardous Substances Data)

Usage

General Description

(R)-3-Mercapto-piperidine-1-carboxylic acid benzyl ester is a chemical compound that consists of a benzyl ester group attached to the carboxylic acid of (R)-3-mercapto-piperidine-1. (R)-3-Mercapto-piperidine-1-carboxylic acid benzyl ester is commonly used in the synthesis of pharmaceuticals and in chemical research. It is known for its ability to act as a chiral building block in organic synthesis, making it a valuable tool for the creation of complex molecules with specific stereochemical properties. Additionally, (R)-3-Mercapto-piperidine-1-carboxylic acid benzyl ester has been studied for its potential therapeutic applications, particularly in the treatment of neurological conditions. Further research is ongoing to explore its potential uses and to understand its biological and chemical properties.

Upstream product

• 95798-22-4 3-hydroxy-piperidine-1-carboxylic acid benzyl ester 
• 912369-01-8 benzyl 3-(acetylthio)piperidine-1-carboxylate 

Relevant articles and documents

Adventures in Scaffold Morphing: Discovery of Fused Ring Heterocyclic Checkpoint Kinase 1 (CHK1) Inhibitors

Checkpoint kinase 1 (CHK1) inhibitors are potential cancer therapeutics that can be utilized for enhancing the efficacy of DNA damaging agents. Multiple small molecule CHK1 inhibitors from different chemical scaffolds have been developed and evaluated in clinical trials in combination with chemotherapeutics and radiation treatment. Scaffold morphing of thiophene carboxamide ureas (TCUs), such as AZD7762 (1) and a related series of triazoloquinolines (TZQs), led to the identification of fused-ring bicyclic CHK1 inhibitors, 7-carboxamide thienopyridines (7-CTPs), and 7-carboxamide indoles. X-ray crystal structures reveal a key intramolecular noncovalent sulfur-oxygen interaction in aligning the hinge-binding carboxamide group to the thienopyridine core in a coplanar fashion. An intramolecular hydrogen bond to an indole NH was also effective in locking the carboxamide in the preferred bound conformation to CHK1. Optimization on the 7-CTP series resulted in the identification of lead compound 44, which displayed respectable drug-like properties and good in vitro and in vivo potency.